Federal Register / Vol. 71, No. 188 / Thursday, September 28, 2006 / Notices 56995 

Agenda: Committee Discussion. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Closed: October 24, 2006, 12:15 p.m. to 

1:15 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individuals investigators. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Open: October 24, 2006, 1:15 p.m. to 3:45 

p.m. 

Agenda: Committee Discussion. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Closed: October 25, 2006, 3:45 p.m. to 4:45 

p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individuals investigators. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Closed: October 25, 2006, 8 a.m. to 8:30 

a.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individuals investigators. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Open: October 25, 2006, 8:30 am. to 12:15 

p.m. 

Agenda: Committee Discussion. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Closed: October 25, 2006, 12:15 p.m. to 

1:15 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individuals investigators. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Open: October 25, 2006, 1:15 p.m. to 2:30 

p.m. 

Agenda: Committee Discussion. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Closed: October 25, 2006, 2:30 p.m. to 3:30 

p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individuals investigators. 

Place: National Institute on Aging, 

Gerontology Research Center, 5600 Nathan 

Shock Drive, Baltimore, MD 21224. 

Contact Person: Dan L. Longo, MD, 

Scientific Director, National Institute of 

Aging, Gerontology Research Center, 

National Institutes of Health, 5600 Nathan 

Shock Drive, Baltimore, MD 21224–6825, 

410–558–8110, dl14q@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: September 19, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8333 Filed 9–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Molecular Biology. 

Date: October 10, 2006. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Rolf Menzel, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3196, 

MSC 7808, 3126 Bethesda, MD 20892, 301–

435–0952, menzelro@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Pancreas. 

Date: October 13, 2006. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Abubakar A. Shaikh, PhD, 

DVM, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 6168, MSC 7892, Bethesda, MD 20892, 

(301) 435–1042, shaikha@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Molecular 

Oncogenesis. 

Date: October 16–17, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Doubletree Hotel, 1515 

Rhode Island Ave., NW., Washington, DC 

20005. 

Contact Person: Joanna M. Watson, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6046–G, 

MSC 7804, Bethesda, MD 20892, 301–435–

1048, watsonjo@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Viral 

Vectors for Tumor Therapy. 

Date: October 17, 2006. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Eun Ah Cho, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6202, 

MSC 7804, Bethesda, MD 20892, (301) 451–

4467, choe@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Modeling and Analysis of Biological 

Systems Study Section. 

Date: October 22–23, 2006. 

Time: 6 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Malgorzata Klosek, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7849, Bethesda, MD 20892, (301) 435–

2211, klosekm@mail.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Cellular, 

Molecular and Integrative Reproduction 

Study Section. 

Date: October 23–24, 2006. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel, 8120 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Dennis Leszczynski, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6170, 

MSC 7892, Bethesda, MD 20892, (301) 435–

1044, leszczyd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Prion 

Biology and Neurodegeneration. 

Date: October 23–24, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Toby Behar, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4136, 

MSC 7850, Bethesda, MD 20892, (301) 435–

4433, behart@csr.nih.gov. 


sroberts on PROD1PC70 with NOTICES
56996 Federal Register / Vol. 71, No. 188 / Thursday, September 28, 2006 / Notices 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Biomedical 

Imaging and Bioinformatics. 

Date: October 23–24, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Guo Feng Xu, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5122, 

MSC 7854, Bethesda, MD 20892, 301–435–

1032, xuguofen@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Pilot and 

Feasibility Studies in Digestive Diseases and 

Nutrition (R21). 

Date: October 23, 2006. 

Time: 8 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Clarion Hotel Bethesda Park, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Peter J. Perrin, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2180, 

MSC 7818, Bethesda, MD 20892, (301) 435–

0682, perrinp@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflicts: CIGP, GCMB, GMPB and HBPP. 

Date: October 23–24, 2006. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Patricia Greenwel, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2174, 

MSC 7818, Bethesda, MD 20892, (301) 435–

1169, greenwep@csr.nih.gov. 

Name of Committee: Cardiovascular 

Sciences Integrated Review Group; Vascular 

Cell and Molecular Biology Study Section. 

Date: October 23–24, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel and Executive 

Meeting Center, 8120 Wisconsin Avenue, 

Bethesda, MD 20814. 

Contact Person: Anshumali Chaudhari, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4124, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1210, chaudhaa@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Arthritis, Connective Tissue and Skin Study 

Section. 

Date: October 23–24, 2006. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Aftab A. Ansari, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4108, 

MSC 7814, Bethesda, MD 20892, (301) 594–

6376, ansaria@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Central Visual 

Processing Study Section. 

Date: October 24–25, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Michael A. Steinmetz, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5172, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1247, steinmem@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Microbiology Integrated Review Group; 

Prokaryotic Cell and Molecular Biology 

Study Section. 

Date: October 24–25, 2006. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: St. Gregory Hotel, 2033 M Street, 

NW., Washington, DC 20036. 

Contact Person: Diane L. Stassi, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892, (301) 435–

2514, stassid@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; MEG 

Technology. 

Date: October 24, 2006 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Lee Rosen, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 5116, MSC 7854, 

Bethesda, MD 20892, (301) 435–1171, 

rosenl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Vision. 

Date: October 24, 2006. 

Time: 2 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Judith A. Finkelstein, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5178, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1249, finkelsj@csr.nih.gov. 

Name of Committee: Health of the 

Population Integrated Review Group; 

Neurological, Aging and Musculoskeletal 

Epidemiology Study Section. 

Date: October 25–26, 2006. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hotel and Corporate 

Quarters, 1615 Rhode Island Avenue, NW., 

Washington, DC 20036. 

Contact Person: Heidi B. Friedman, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1012A, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1721, hfriedman@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; ZRG1 ONC–

P (02): Boron Neutron Capture Therapy. 

Date: October 25, 2006. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Zhiqiang Zou, MD, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

MSC 7804, Bethesda, MD 20892, (301) 451–

0132, zouzhiq@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Neurobiology of Sleep and Circadian 

Rhythms. 

Date: October 25, 2006. 

Time: 2 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Gamil C. Debbas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1018, debbasg@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Shared 

Instruments: Computers and Lithography. 

Date: October 25, 2006. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Sally Ann Amero, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4190, 

MSC 7849, Bethesda, MD 20892, (301) 435–

1159, ameros@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; CommunityBased Participation in Research—R21s. 

Date: October 25–26, 2006. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Marriott at 

Washingtonian Center, 204 Boardwalk Place, 

Gaithersburg, MD 20878. 

Contact Person: Alfonso R. Latoni, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1735, latonia@csr.nih.gov. 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 188 / Thursday, September 28, 2006 / Notices 56997 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Assays and 

Detectors. 

Date: October 25–26, 2006. 

Time: 6 p.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Clarion Hotel Bethesda Park, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Geoffrey White, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5148, 

MSC 7849, Bethesda, MD 20892, (301) 435–

1735, whitege@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.983, National 

Institutes of Health, HHS) 

Dated: September 19, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8331 Filed 9–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Toxicology Program (NTP), 

NTP Interagency Center for the 

Evaluation of Alternative Toxicological 

Methods (NICEATM); Notice of 

Availability of a Revised List of 

Recommended Reference Substances 

for Validation of In Vitro Estrogen and 

Androgen Receptor Binding and 

Transcriptional Activation Assays 

AGENCY: National Institute of 

Environmental Health Sciences 

(NIEHS), National Institutes of Health 

(NIH). 

ACTION: Notice of the availability of a 

revised list of recommended reference 

substances. 

SUMMARY: NICEATM announces the 

availability of an addendum to the 

report, ‘‘Interagency Coordinating 

Committee on the Validation of 

Alternative Methods (ICCVAM) 

Evaluation of In Vitro Test Methods for 

Detecting Potential Endocrine 

Disruptors: Estrogen Receptor and 

Androgen Receptor Binding and 

Transcriptional Activation Assays’’

[NIH Publication 03–4503]. The 

addendum describes the rationale for 

revisions to the original list of 

recommended reference substances for 

validation of in vitro estrogen receptor 

(ER) and androgen receptor (AR) 

binding and transcriptional activation 

(TA) assays. 

SUPPLEMENTARY INFORMATION: 

Background 

In April 2000, the Environmental 

Protection Agency (EPA) asked ICCVAM 

to evaluate the validation status of in 

vitro ER and AR binding and TA assays 

that were proposed as possible 

components of the EPA Endocrine 

Disruptor Screening Program Tier 1 

screening battery. ICCVAM agreed to 

evaluate these test methods based on 

their potential interagency applicability 

and public health significance. 

NICEATM subsequently compiled 

available data and information on in 

vitro ER and AR binding and TA assays 

in four draft Background Review 

Documents (BRDs) (available at http:// 

iccvam.niehs.nih.gov/methods/ 

endocrine.htm). 

In collaboration with the ICCVAM 

Endocrine Disruptor Working Group, 

NICEATM organized an independent 

scientific evaluation of the validation 

status of the four types of in vitro 

endocrine disruptor screening test 

methods on May 20–21, 2002, in 

Research Triangle Park, NC (Federal 

Register, Vol. 66, No. 57, pp. 16278–

16279, March 23, 2001 and Federal 

Register, Vol. 66, No. 67, pp. 16415–

16416, April 5, 2002, available at http:// 

iccvam.niehs.nih.gov/methods/ 

endocrine.htm). 

The final BRDs and the ICCVAM Test 

Method Evaluation Report, which 

includes the expert panel report, public 

comments, and other relevant 

documents, were published in May 

2003 and announced in the Federal 

Register notice (Vol. 68, No. 106, pp. 

33171–33172, June 3, 2003, available at 

http://iccvam.niehs.nih.gov/methods/ 

endocrine.htm). 

NICEATM recently reviewed the 

commercial availability and cost for the 

78 substances recommended by 

ICCVAM for use in in vitro ER and AR 

binding and TA validation studies. A 

minimum of 44 substances are 

recommended for AR binding and TA 

assays, while a minimum of 53 

substances are recommended for ER 

binding and TA assays. This review 

indicated that three substances 

(anastrazole, CGS 18320B, and 

fadrozole) are not commercially 

available, one substance has restricted 

commercial availability (ICI 182,780) 

and six others (actinomycin D, 

hydroxyflutamide, 4-hydroxytamoxifen, 

methyltrienolone, 12-Otetradecanoylphorbol-13-acetate, 

zearalenone) have costs that are 

considered excessive. ICCVAM has 

replaced the four substances, which are 

not commercially available or have 

restricted availability, with ones having 

similar ER and AR activity profiles (4- 

hydroxyandrostenedione, chrysin, 

dicofol, raloxifene HCl). 19- 

nortestosterone and resveratrol were 

identified as replacements for two of the 

expensive substances, metyltrienolone 

and zearalenone respectively. NICEATM 

sought to replace four of the highly 

priced substances (actinomycin D, 

hydroxyflutamide, 4-hydroxytamoxifen, 

12-O-tetradecanoylphorbol-13-acetate), 

but was unable to identify suitable 

replacements because of their unique 

activity profiles and/or chemical/ 

physical properties. The proposed 

revisions were made available for public 

comment in March 2006 (Federal 

Register, Vol. 71, No. 51, pp. 13597–

13598, March 16, 2006) and no 

comments were received. The final 

revised list of 78 reference substances 

recommended for validation of in vitro 

ER and AR binding and TA validation 

studies and a discussion about the 

revisions are now available in the 

document, ‘‘Addendum to the ICCVAM 

Evaluation of In Vitro Test Methods for 

Detecting Potential Endocrine 

Disruptors: Estrogen Receptor and 

Androgen Receptor Binding and 

Transcriptional Activation Assays.’’ The 

addendum is available on the ICCVAM/ 

NICEATM Web site at http:// 

iccvam.niehs.nih.gov see ‘‘Test Method 

Evaluations’’ or by contacting NICEATM 

(requests should be sent by mail, fax, or 

e-mail to Dr. William S. Stokes, 

NICEATM Director, NIEHS, P. O. Box 

12233, MD EC–17, Research Triangle 

Park, NC, 27709, (phone) 919–541–

2384, (fax) 919–541–0947, (e-mail) 

niceatm@niehs.nih.gov.). 

Background Information on ICCVAM 

and NICEATM 

ICCVAM is an interagency committee 

composed of representatives from 15 

Federal regulatory and research agencies 

that use or generate toxicological 

information. ICCVAM conducts 

technical evaluations of new, revised, 

and alternative methods with regulatory 

applicability and promotes the scientific 

validation and regulatory acceptance of 

toxicological test methods that more 

accurately assess the safety and hazards 

of chemicals and products and that 

refine, reduce, or replace animal use. 

The ICCVAM Authorization Act of 2000 

(42 U.S.C. 285) establishes ICCVAM as 

a permanent interagency committee of 

the NIEHS under the NICEATM. 

NICEATM administers the ICCVAM and 

provides scientific and operational 

support for ICCVAM-related activities. 

NICEATM and ICCVAM work 

collaboratively to evaluate new and 

improved test methods applicable to the 

needs of Federal agencies. Additional 

information about ICCVAM and 


sroberts on PROD1PC70 with NOTICES